KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Gross Margin (2019 - 2025)

Esperion Therapeutics (ESPR) has disclosed Gross Margin for 7 consecutive years, with 52.71% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Margin fell 1381.0% year-over-year to 52.71%, compared with a TTM value of 58.2% through Sep 2025, down 2338.0%, and an annual FY2024 reading of 79.36%, up 1655.0% over the prior year.
  • Gross Margin was 52.71% for Q3 2025 at Esperion Therapeutics, down from 65.35% in the prior quarter.
  • Across five years, Gross Margin topped out at 95.57% in Q2 2021 and bottomed at 51.3% in Q2 2022.
  • Average Gross Margin over 5 years is 67.38%, with a median of 65.35% recorded in 2025.
  • The sharpest move saw Gross Margin tumbled -4428bps in 2022, then soared 4058bps in 2024.
  • Year by year, Gross Margin stood at 67.05% in 2021, then grew by 16bps to 77.89% in 2022, then decreased by -17bps to 64.49% in 2023, then decreased by -2bps to 62.91% in 2024, then decreased by -16bps to 52.71% in 2025.
  • Business Quant data shows Gross Margin for ESPR at 52.71% in Q3 2025, 65.35% in Q2 2025, and 51.48% in Q1 2025.